Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
3.
J Infect Chemother ; 27(2): 139-150, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33277177

RESUMEN

A nationwide surveillance of the antimicrobial susceptibility of pediatric patients to bacterial pathogens was conducted by Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in Japan in 2017. The isolates were collected from 18 medical facilities between March 2017 and May 2018 by the three societies. Antimicrobial susceptibility testing was conducted at the central laboratory (Infection Control Research Center, Kitasato University, Tokyo) according to the methods recommended by the Clinical Laboratory Standards Institute. Susceptibility testing was evaluated in 926 strains (331 Streptococcus pneumoniae, 360 Haemophilus influenzae, 216 Moraxella catarrhalis, 5 Streptococcus agalactiae, and 14 Escherichia coli). The ratio of penicillin-resistant S. pneumoniae was 0% based on CLSI M100-ED29 criteria. However, three meropenem or tosufloxacin resistant S. pneumoniae isolates were obtained. Among H. influenzae, 13.1% of them were found to be ß-lactamase-producing ampicillin resistant strains, while 20.8% were ß-lactamase non-producing ampicillin-resistant strains. No capsular type b strains were detected. In M. catarrhalis, 99.5% of the isolates were ß-lactamase-producing strains. All S. agalactiae and E. coli strains were isolated from sterile body sites (blood or cerebrospinal fluid). The ratio of penicillin-resistant S. agalactiae was 0%, while that of extended spectrum ß-lactamase-producing E. coli was 14.3%.


Asunto(s)
Enfermedades Transmisibles , Infecciones del Sistema Respiratorio , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Niño , Enfermedades Transmisibles/tratamiento farmacológico , Farmacorresistencia Bacteriana , Escherichia coli , Haemophilus influenzae , Humanos , Japón/epidemiología , Pruebas de Sensibilidad Microbiana , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Tokio
4.
Sensors (Basel) ; 20(23)2020 Dec 07.
Artículo en Inglés | MEDLINE | ID: mdl-33297390

RESUMEN

We found that a magnetic sensor made of a coil wound around a 5 f0.1 mm (Fe0.06Co0.94)72.5Si2.5B15 (FeCoSiB) amorphous wire could operate in a wide temperature range from room temperature to liquid helium temperature (4.2 K). The low-temperature sensing element of the sensor was connected to the room-temperature driving circuit by only one coaxial cable with a diameter of 1 mm. The one-cable design of the magnetic sensor reduced the heat transferring through the cable to the liquid helium. To develop a magnetic sensing system capable of operating at liquid helium temperature, we evaluated the low-temperature properties of the FeCoSiB magnetic sensor.

5.
Pediatr Int ; 59(10): 1123-1125, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29081076

RESUMEN

The sensitivity and specificity of a new rapid Mycoplasma pneumoniae antigen immunochromatography (IC) test, DK-MP-001, were determined using particle agglutination (PA) antibody response and loop-mediated isothermal amplification (LAMP) gene detection as the gold standard. Of 165 patients, 59 were diagnosed with M. pneumoniae infection based on a ≥fourfold rise of serum PA antibody during the course of the illness. Of the first visit swabs, 60 were positive for M. pneumoniae on LAMP, and 49 were positive for M. pneumoniae antigen on IC test. Compared with PA antibody and LAMP, the sensitivity/specificity of the IC test were 81.4% (48/59) and 99.1% (105/106); and 81.7% (49/60) and 100% (105/105), respectively. IC test detected antigen in pharyngeal swabs more sensitively than in nasal swabs for the same subjects (P < 0.05). The IC test performs well enough to be used with pharyngeal swabs at the first examination.


Asunto(s)
Cromatografía de Afinidad/métodos , Neumonía por Mycoplasma/diagnóstico , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Sensibilidad y Especificidad , Adulto Joven
6.
J Infect Chemother ; 23(11): 785-787, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28729050

RESUMEN

Streptococcus pneumoniae is a main causative agent of serious invasive bacterial infections. However, concurrent infection with invasive pneumococcal disease (IPD) and viral infectious mononucleosis (IM) is rare. We report an infant with serotype 6C infection causing IPD occurring simultaneously with IM. A previously healthy 11-month-old girl referred to our hospital because of fever, leukopenia, and elevated C-reactive protein presented to us with disturbance of consciousness, tachycardia, tachypnea and agranulocytosis. Other findings included tonsillitis with purulent exudates and white spots, bilateral cervical adenopathy, and hepatosplenomegaly. We diagnosed her illness as sepsis and administered a broad-spectrum antibiotic, an antiviral agent, and granulocyte transfusions. After treatment was initiated, fever gradually decreased and general condition improved. IPD was diagnosed based upon isolation of S. pneumoniae of serotype 6C from blood cultures obtained on admission. Concurrently the girl had IM, based upon quantitation of Epstein-Barr viral DNA copies in blood and fluctuating serum antibody titers. Although simultaneous IPD and IM is a rare occurrence, this possibility is important to keep in mind.


Asunto(s)
Agranulocitosis/complicaciones , Fiebre/complicaciones , Mononucleosis Infecciosa/complicaciones , Infecciones Neumocócicas/complicaciones , Streptococcus pneumoniae/aislamiento & purificación , Agranulocitosis/sangre , Agranulocitosis/microbiología , Agranulocitosis/terapia , Antibacterianos/uso terapéutico , Proteína C-Reactiva/análisis , Citomegalovirus/aislamiento & purificación , Femenino , Fiebre/sangre , Fiebre/tratamiento farmacológico , Fiebre/microbiología , Vacuna Neumocócica Conjugada Heptavalente/administración & dosificación , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Lactante , Mononucleosis Infecciosa/sangre , Mononucleosis Infecciosa/microbiología , Mononucleosis Infecciosa/terapia , Transfusión de Leucocitos , Infecciones Neumocócicas/sangre , Infecciones Neumocócicas/microbiología , Infecciones Neumocócicas/terapia , Reacción en Cadena de la Polimerasa , Serogrupo , Serotipificación , Streptococcus pneumoniae/efectos de los fármacos , Streptococcus pneumoniae/inmunología
7.
Int J Antimicrob Agents ; 50(2): 255-257, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28579455

RESUMEN

Macrolide-resistant Mycoplasma pneumoniae (MRMP) has emerged and is increasing worldwide. In a 2011 outbreak of MRMP infections in Japan, symptoms failed to improve in many patients who initially received macrolides; the therapeutic agent was then changed to minocycline (MIN), doxycycline (DOX) or tosufloxacin (TFX). In this study, the bactericidal effects of these three agents against MRMP were evaluated. Time-kill kinetics against MRMP and macrolide-susceptible M. pneumoniae (MSMP) were determined for 5 days at concentrations corresponding to the respective minimum inhibitory concentration (MIC) and 2 × MIC, i.e. 1 µg/mL and 2 µg/mL for MIN, 0.5 µg/mL and 1 µg/mL for DOX, and 0.5 µg/mL and 1 µg/mL for TFX. The post-antibiotic effects (PAE) of these agents in culture against MRMP were also examined based on their pharmacokinetic parameters in children. Following exposure of MRMP and MSMP to up to twice the respective MICs of MIN, DOX and TFX, viable cells initially numbering 106 CFU/mL had decreased similarly to 103 CFU/mL after 4 days. Clarithromycin and azithromycin showed good bactericidal action against MSMP but not against MRMP. PAEs against MRMP appeared superior with MIN and DOX compared with TFX. In infection with M. pneumoniae having a generation time exceeding 6 h, a therapeutic agent must be selected in consideration of pharmacokinetic parameters, not MICs alone.


Asunto(s)
Antibacterianos/farmacología , Doxiciclina/farmacología , Farmacorresistencia Bacteriana , Fluoroquinolonas/farmacología , Macrólidos/farmacología , Minociclina/farmacología , Mycoplasma pneumoniae/efectos de los fármacos , Naftiridinas/farmacología , Niño , Preescolar , Recuento de Colonia Microbiana , Brotes de Enfermedades , Femenino , Humanos , Lactante , Recién Nacido , Japón/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Mycoplasma pneumoniae/aislamiento & purificación , Neumonía por Mycoplasma/epidemiología , Neumonía por Mycoplasma/microbiología , Factores de Tiempo
8.
Pediatr Int ; 58(3): 192-201, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26259099

RESUMEN

BACKGROUND: Streptococcus pneumoniae is a major causative pathogen of pneumonia in children. The Drug-Resistant Pathogen Surveillance Group in Pediatric Infectious Disease conducted a nationwide surveillance of S. pneumoniae in 2000-2001, 2004, 2007, 2010 and 2012, and investigated changes in drug resistance of S. pneumoniae. METHODS: All strains of S. pneumoniae were isolated from clinical specimens collected from pediatric patients. The minimun inhibitory concentration was measured and the strains were classified according to the Clinical Laboratory Standards Institute criteria. The isolation rates of penicillin-intermediate resistant S. pneumoniae (PISP) and penicillin-resistant S. pneumoniae (PRSP) were compared based on seven patient factors. Logistic regression analysis was also performed. RESULTS: The sum of the isolation rates for PISP and PRSP for each period was 64.6%, 67.0%, 56.2%, 76.9% and 49.5%, respectively. Among the patient factors, age category 1 (<3 years, ≥3 years), age category 2 (infant, toddler and preschooler, schoolchild), siblings (absence, presence), and pre-treatment with antimicrobial agents (absence, presence) were associated with significant differences in the isolation rate of PISP + PRSP. An interaction was observed between pre-treatment with antimicrobial agents and schoolchild, and the isolation rate of PISP + PRSP was higher in patients with both pre-treatment with antimicrobial agents and schoolchild. CONCLUSION: Although some changes were observed in the rate of resistance of S. pneumoniae, an increasing trend was not observed. Both pre-treatment with antimicrobial agents and age were associated with resistance, and an interaction was observed between pre-treatment with antimicrobial agents and schoolchild.


Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Infecciones Neumocócicas/epidemiología , Streptococcus pneumoniae/aislamiento & purificación , Niño , Preescolar , Femenino , Humanos , Incidencia , Lactante , Japón/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Infecciones Neumocócicas/tratamiento farmacológico , Infecciones Neumocócicas/microbiología , Streptococcus pneumoniae/efectos de los fármacos
9.
J Infect Chemother ; 19(3): 432-40, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23108427

RESUMEN

Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae are the main pathogens causing community-acquired pneumonia (CAP). We identified S. pneumoniae (n = 241), H. influenzae (n = 123), and M. pneumoniae (n = 54) as causative pathogens from clinical findings and blood tests from pediatric CAP patients (n = 903) between April 2008 and April 2009. Identification of genes mediating antimicrobial resistance by real-time PCR was performed for all isolates of these three pathogens, as was antibiotic susceptibility testing using an agar dilution method or broth microdilution method. The genotypic (g) resistance rate was 47.7 % for penicillin-resistant S. pneumoniae (gPRSP) possessing abnormal pbp1a, pbp2x, and pbp2b genes, 62.6 % for ß-lactamase-nonproducing, ampicillin-resistant (gBLNAR) H. influenzae possessing the amino acid substitutions Ser385Thr and Asn526Lys, and 44.4 % for macrolide-resistant M. pneumoniae (gMRMP) possessing a mutation of A2063G, A2064G, or C2617A. Serotype 6B (20.3 %) predominated in S. pneumoniae, followed by 19F (15.4 %), 14 (14.5 %), 23F (12.0 %), 19A (6.2 %), and 6C (5.4 %). Coverage for the isolates by heptavalent pneumococcal conjugate vaccine (PCV7) and PCV13, respectively, was calculated as 68.5 and 80.9 %. A small number of H. influenzae were identified as type b (6.5 %), type e (0.8 %), or type f (0.8 %); all others were nontypeable. Proper use of antibiotics based on information about resistance in CAP pathogens is required to control rapid increases in resistance. Epidemiological surveillance of pediatric patients also is needed to assess the effectiveness of PCV7 and Hib vaccines after their introduction in Japan.


Asunto(s)
Infecciones Comunitarias Adquiridas/microbiología , Haemophilus influenzae/efectos de los fármacos , Mycoplasma pneumoniae/efectos de los fármacos , Neumonía Bacteriana/microbiología , Streptococcus pneumoniae/efectos de los fármacos , Antibacterianos/farmacología , ADN Bacteriano , Farmacorresistencia Bacteriana , Genotipo , Haemophilus influenzae/genética , Humanos , Pruebas de Sensibilidad Microbiana , Mycoplasma pneumoniae/genética , Streptococcus pneumoniae/genética
10.
Clin Infect Dis ; 55(12): 1642-9, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22972867

RESUMEN

BACKGROUND: Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumonia in children and young adults. Outbreaks typically occur at intervals of several years. In 2011, a widespread outbreak was associated with macrolide-resistant M. pneumoniae (MRMP) in Japanese children, often those of school age. METHODS: Two hundred fifty-eight children were diagnosed with M. pneumoniae-associated pneumonia based on chest radiography, real-time polymerase chain reaction (PCR), and antibody titers between January and December 2011. Mycoplasma pneumoniae cultures obtained from nasopharyngeal samples using appropriate broth were subjected to real-time PCR, by which decreases in M. pneumoniae in patients treated with minocycline (MIN), doxycycline (DOX), or tosufloxacin (TFX) were calculated. Mutations of the 23S ribosomal RNA gene that confer high resistance to macrolides in M. pneumoniae were identified by DNA sequencing. RESULTS: Among 202 M. pneumoniae isolates from M. pneumoniae-associated pneumonia patients, 176 (87.1%) were MRMP. Macrolide-resistant M. pneumoniae infection was significantly related to school age (P < .01) and initial administration of macrolides (P < .01). Minocycline or DOX (n = 125) or TFX or levofloxacin (n = 15) was used for definitive treatment of MRMP patients. Minocycline or DOX was significantly more effective than TFX (P ≤ .05) in achieving defervescence within 24 hours and in decreasing numbers of M. pneumoniae DNA copies 3 days after initiation. CONCLUSIONS: Macrolides are inappropriate as first-choice agents against MRMP in terms of shortening the clinical course and decreasing M. pneumoniae. Control and prevention of MRMP outbreaks in children require early decreases in M. pneumoniae as well as improvement of clinical findings.


Asunto(s)
Antibacterianos/uso terapéutico , Brotes de Enfermedades/estadística & datos numéricos , Doxiciclina/uso terapéutico , Minociclina/uso terapéutico , Mycoplasma pneumoniae/aislamiento & purificación , Neumonía por Mycoplasma/tratamiento farmacológico , Adolescente , Distribución de Chi-Cuadrado , Niño , Preescolar , Farmacorresistencia Bacteriana , Femenino , Humanos , Lactante , Japón/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Neumonía por Mycoplasma/epidemiología , Estudios Prospectivos , Resultado del Tratamiento
11.
J Infect Chemother ; 18(6): 832-40, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22569795

RESUMEN

To evaluate pathogens in pediatric inpatients with community-acquired pneumonia (CAP), an Acute Respiratory Diseases Study Group organized by ten Japanese medical institutions devised a rapid, reliable process based on real-time PCR results in nasopharyngeal swab samples plus admission blood test results. From April 2008 to April 2009, we enrolled 903 children with CAP based on chest radiographs and clinical findings who were hospitalized within 5 days of onset. Comprehensive real-time PCR was used to detect 6 bacteria and 11 respiratory viruses. The swab specimens also were used for bacterial cultures. After initial determination of presence or absence of viral and mycoplasmal infections, significant bacterial contributions were defined by bacterial identification, clinical efficacy of antimicrobial agent, and reference to blood test results. Children were stratified by age: below 1 year, 1 year, 2-5 years, or at least 6 years old. Among patients studied, 34.4 % were diagnosed with viral infection; 21.8 %, bacterial infection; 17.5 %, viral/bacterial co-infection; 5.9 %, mycoplasmal infection; 0.3 %, mycoplasmal/bacterial co-infection; and 1.7 %, viral/mycoplasmal co-infection. The remaining 18.4 % had unknown pathogens. Purely viral infection was suggested mainly in infants younger than 1 year; mycoplasmal infection typically occurred in children at least 6 years old. Our results suggest usefulness of real-time PCR for nasopharyngeal samples together with blood tests in estimating etiologic agents in clinical settings.


Asunto(s)
Infecciones Comunitarias Adquiridas/microbiología , Neumonía/microbiología , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Bacterias/genética , Bacterias/aislamiento & purificación , Infecciones Bacterianas/sangre , Infecciones Bacterianas/epidemiología , Infecciones Bacterianas/microbiología , Infecciones Bacterianas/virología , Proteína C-Reactiva/metabolismo , Distribución de Chi-Cuadrado , Niño , Preescolar , Infecciones Comunitarias Adquiridas/sangre , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/virología , Humanos , Lactante , Recuento de Leucocitos , Neumonía/sangre , Neumonía/epidemiología , Neumonía/virología , Virosis/sangre , Virosis/epidemiología , Virosis/microbiología , Virosis/virología , Virus/genética , Virus/aislamiento & purificación
12.
EMBO J ; 30(18): 3799-811, 2011 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-21822217

RESUMEN

Two interacting ribosome biogenesis factors, Ebp2 and Rrs1, associate with Mps3, an essential inner nuclear membrane protein. Both are found in foci along the nuclear periphery, like Mps3, as well as in the nucleolus. Temperature-sensitive ebp2 and rrs1 mutations that compromise ribosome biogenesis displace the mutant proteins from the nuclear rim and lead to a distorted nuclear shape. Mps3 is known to contribute to the S-phase anchoring of telomeres through its interaction with the silent information regulator Sir4 and yKu. Intriguingly, we find that both Ebp2 and Rrs1 interact with the C-terminal domain of Sir4, and that conditional inactivation of either ebp2 or rrs1 interferes with both the clustering and silencing of yeast telomeres, while telomere tethering to the nuclear periphery remains intact. Importantly, expression of an Ebp2-Mps3 fusion protein in the ebp2 mutant suppresses the defect in telomere clustering, but not its defects in growth or ribosome biogenesis. Our results suggest that the ribosome biogenesis factors Ebp2 and Rrs1 cooperate with Mps3 to mediate telomere clustering, but not telomere tethering, by binding Sir4.


Asunto(s)
Proteínas Portadoras/metabolismo , ADN de Hongos/metabolismo , Proteínas de la Membrana/metabolismo , Proteínas Nucleares/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , Saccharomyces cerevisiae/metabolismo , Telómero/metabolismo , Unión Proteica , Proteínas Reguladoras de Información Silente de Saccharomyces cerevisiae/metabolismo
13.
Emerg Infect Dis ; 17(2): 279-82, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21291606

RESUMEN

To describe clinical aspects of pandemic (H1N1) 2009 virus-associated pneumonia in children, we studied 80 such children, including 17 (21%) with complications, who were admitted to 5 hospitals in Japan during August-November 2009 after a mean of 2.9 symptomatic days. All enrolled patients recovered (median hospitalization 6 days). Timely access to hospitals may have contributed to favorable outcomes.


Asunto(s)
Subtipo H1N1 del Virus de la Influenza A/patogenicidad , Gripe Humana/complicaciones , Gripe Humana/epidemiología , Pandemias , Neumonía Viral/epidemiología , Antivirales/uso terapéutico , Niño , Brotes de Enfermedades , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Gripe Humana/virología , Japón/epidemiología , Masculino , Neumonía Viral/diagnóstico , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/microbiología , Factores de Riesgo , Factores de Tiempo
14.
J Infect Chemother ; 17(2): 238-45, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20827563

RESUMEN

We analyzed the clinical features of inpatients at a Japanese pediatric department who were infected with pandemic (H1N1) 2009 virus. Study participants included 46 children hospitalized from July 2009 to January 2010. Infection with the virus was confirmed using real-time reverse transcriptase polymerase chain reaction (RT-PCR). The epidemic month was October 2009; 34 patients were boys, and median age was 7 years. Pandemic influenza-associated respiratory diseases included pneumonia (n = 42), bronchitis (n = 3), and pharyngitis (n = 1). The median time from onset to admission was 3 days. Children were divided into those with severe (n = 32) versus nonsevere illnesses (n = 14) according to Japanese guidelines. Significant features in the severe group were younger age, previous asthmatic attack, exacerbation of asthma, decreased oxygen saturation, elevated white blood cell/neutrophil counts and serum lactate dehydrogenase, and longer times from admission to being afebrile and discharged. Both groups showed lymphopenia at admission. Additional infection with Streptococcus pneumoniae was frequent in the severe group. Whereas 44 patients received antiviral therapy (median times from onset to initiation 2 days), 32 received antibiotics (median duration 7 days). All children recovered, with a median hospital stay of 8 days. Our observations suggest that history of asthma and preschool age might be risk factors for severe illness. Prompt initiation of antiviral and antibiotic treatments should be considered to prevent development of severe illness.


Asunto(s)
Hospitalización/estadística & datos numéricos , Subtipo H1N1 del Virus de la Influenza A/patogenicidad , Gripe Humana/complicaciones , Gripe Humana/epidemiología , Pandemias , Antibacterianos/uso terapéutico , Antivirales/uso terapéutico , Bronquitis/complicaciones , Bronquitis/tratamiento farmacológico , Bronquitis/epidemiología , Niño , Preescolar , Femenino , Humanos , Lactante , Subtipo H1N1 del Virus de la Influenza A/clasificación , Subtipo H1N1 del Virus de la Influenza A/genética , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/tratamiento farmacológico , Gripe Humana/virología , Japón/epidemiología , Masculino , Pediatría , Faringitis/complicaciones , Faringitis/tratamiento farmacológico , Faringitis/epidemiología , Neumonía/complicaciones , Neumonía/tratamiento farmacológico , Neumonía/epidemiología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Índice de Severidad de la Enfermedad
15.
Kansenshogaku Zasshi ; 84(1): 42-7, 2010 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-20170013

RESUMEN

We retrospectively reviewed the background, clinical features, blood tests, and complications in the 720 children seen for acute respiratory tract infection from July 2004 to December 2005. Of these, 75 (10.5%) were diagnosed with pneumonia due to respiratory syncytial virus (RSV) and 19 (2.6%) with pneumonia due to human metapneumovirus (hMPV) based on multiplex PCR analysis of nasopharyngeal samples. RSV was PCR-positive mostly in winter, -from November to January-, and hMPV mostly in spring, -from March to June. The mean RSV pneumonia group age was 1.3 +/- 1.4 years and in the hMPV pneumonia group 3.0 +/- 3.1 years, showing a statistically significant differences in the age of virus onset. Clinically the RSV group showed more rhinorrhea and wheezing (p < 0.05) and the hMPV group a higher maximum body temperature and a longer wheezing duration (p < 0.05). Fever, cough, vomiting, diarrhea, fever frequency, and C-reactive protein level were similar in both groups (p > 0.05). Complication prevalence was 49.3% in the RSV group and 42.1% in the hMPV group. Acute otitis media was seen more often in the RSV group (32.0%) and febrile convulsion more often in the hMPV group (15.8%) (p > 0.05). These findings may be helpful in clinically diagnosing community-acquired pneumonia due to RSV or hMPV.


Asunto(s)
Infecciones Comunitarias Adquiridas , Metapneumovirus , Infecciones por Paramyxoviridae , Neumonía Viral , Infecciones por Virus Sincitial Respiratorio , Factores de Edad , Infecciones Comunitarias Adquiridas/epidemiología , Femenino , Humanos , Lactante , Masculino , Infecciones por Paramyxoviridae/epidemiología , Neumonía Viral/epidemiología , Infecciones por Virus Sincitial Respiratorio/epidemiología , Estudios Retrospectivos , Tokio/epidemiología
16.
Kansenshogaku Zasshi ; 84(1): 69-72, 2010 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-20170018

RESUMEN

Salmonella enterica serovar Senftenberg may very rarely cause splenic abscess, which can be diagnosed using gallium scintigraphy and drained. A 14-year-old boy admitted for stomachache, diarrhea and fever and diagnosed from his symptoms as having enteritis did not respond when treated with fosfomycin, meropenem, and clindamycin. A low-density splenic area seen in abdominal computed tomography on admission did not show contrast medium enhancement. Gallium scintigraphy on hospital day 10, however, showed abnormal splenic accumulation confirming the splenic abscess diagnosis, after which we punctured and drained the abscessout. S. Senftenberg was isolated from pus aspirated pus from the abscess, after which responded well to ceftriaxone and levofloxacin. Follow-up gallium scintigraphy on hospital day 24 showed that the abnormal splenic accumulation had disappeared, after which he has been followed up with abdominal ultrasonography and blood tests as an outpatient. He has experienced no relapse of splenic abscess.


Asunto(s)
Absceso/microbiología , Salmonella enterica/aislamiento & purificación , Enfermedades del Bazo/microbiología , Adolescente , Humanos , Masculino , Infecciones por Salmonella
17.
J Infect Chemother ; 15(6): 380-3, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20012728

RESUMEN

In recent years, the increased prevalence of macrolide-resistant Mycoplasma pneumoniae (MR-M. pneumoniae) has become a significant issue in Japan. We isolated 94 strains of M. pneumoniae, and determined the minimum inhibitory concentrations (MICs) of macrolides and other antimicrobial agents for these strains. We also performed a comparative clinical evaluation of macrolide efficacy for cases of MR-M. pneumoniae infections and cases of macrolide-sensitive Mycoplasma pneumoniae infections (MS-M. pneumoniae). Of the 94 isolates of M. pneumoniae, 64 (68.1%) were classified as MS-M. pneumoniae and 30 (31.9%) as MR-M. pneumoniae strains. The clinical study included an assessment of 47 pediatric cases of MS-M. pneumoniae and 22 pediatric cases of MR-M. pneumoniae. The patient demographics, such as sex, age, the period from the onset of the infection to the first examination, laboratory findings, diagnosis, and the severity of symptoms, showed no significant difference between the two study groups. However, the efficacy of macrolide treatment was 91.5% for MS-M. pneumoniae and 22.7% for MR-M. pneumoniae, a statistically significant difference (P < 0.01). Although M. pneumoniae infection is generally considered a treatable condition, the increasing prevalence of macrolide-resistant strains of M. pneumoniae has become a significant clinical issue in pediatric patients, and it is therefore necessary to give careful consideration to the appropriate antimicrobial therapy for MR-M. pneumoniae infection.


Asunto(s)
Antibacterianos/farmacología , Macrólidos/farmacología , Mycoplasma pneumoniae/efectos de los fármacos , Adolescente , Antibacterianos/uso terapéutico , Niño , Preescolar , Farmacorresistencia Bacteriana , Femenino , Humanos , Lactante , Macrólidos/uso terapéutico , Masculino , Pruebas de Sensibilidad Microbiana , Mycoplasma pneumoniae/genética , Mycoplasma pneumoniae/aislamiento & purificación , Neumonía por Mycoplasma/tratamiento farmacológico , Neumonía por Mycoplasma/microbiología
19.
J Infect Chemother ; 15(4): 243-7, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19688244

RESUMEN

An 81-year-old woman with no underlying systemic illness was hospitalized with fever, muscle weakness, and sputum without cough for 2 days. Chest imaging showed consolidation in the left lower lobe. Real-time polymerase chain reaction (PCR) for six respiratory bacteria and 12 respiratory viruses performed on sputum obtained on admission showed Mycoplasma pneumoniae DNA, with no evidence of other pathogens. M. pneumoniae was confirmed to be the causative agent by serologic data. Variation of mycoplasma quantity in subsequent sputa was analyzed because of persistent sputum production despite treatment with minocycline. Mycoplasma DNA gradually decreased, becoming undetectable 1 week after the completion of 2 weeks of minocycline therapy. Two weeks after the completion of the minocycline therapy, mycoplasma DNA in sputum was strongly detectable again, and oral treatment with clarithromycin was initiated. No pathogen DNA was detected during 2 weeks of clarithromycin therapy or at 2 weeks after completion of this therapy. Although susceptibility tests on three isolates (on admission, 1 week after starting minocycline, and 2 weeks after minocycline cessation), showed no resistance to minocycline or clarithromycin, the infection was, nonetheless, prolonged. Some elderly subjects with mycoplasma pneumonia may show a longer course than that in young persons with pneumonia.


Asunto(s)
Mycoplasma pneumoniae/aislamiento & purificación , Neumonía por Mycoplasma/diagnóstico , Neumonía por Mycoplasma/tratamiento farmacológico , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Claritromicina/uso terapéutico , Infecciones Comunitarias Adquiridas/diagnóstico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Femenino , Anciano Frágil , Humanos , Minociclina/uso terapéutico , Esputo/microbiología
20.
J Infect Chemother ; 15(2): 92-8, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19396518

RESUMEN

We aimed to detect causative pathogens in cerebrospinal fluid (CSF) collected from patients diagnosed with bacterial meningitis by real-time polymerase chain reaction (PCR). In addition to Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae described previously, five other pathogens, Neisseria meningitidis, Escherichia coli, Streptococcus agalactiae, Staphylococcus aureus, and Listeria monocytogenes, were targeted, based on a large-scale surveillance in Japan. Results in CSF from neonates and children (n=150), and from adults (n=18) analyzed by real-time PCR with molecular beacon probes were compared with those of conventional culturing. The total time from DNA extraction from CSF to PCR analysis was 1.5 h. The limit of detection for these pathogens ranged from 5 copies to 28 copies per tube. Nonspecific positive reactions were not recognized for 37 microorganisms in clinical isolates as a negative control. The pathogens were detected in 72.0% of the samples by real-time PCR, but in only 48.2% by culture, although the microorganisms were completely concordant. With the real-time PCR, the detection rate of H. influenzae from CSF was high, at 45.2%, followed by S. pneumoniae (21.4%), S. agalactiae (2.4%), E. coli (1.8%), L. monocytogenes (0.6%), and M. pneumoniae (0.6%). The detection rate with PCR was significantly better than that with cultures in patients with antibiotic administration (chi2=18.3182; P=0.0000). In conclusion, detection with real-time PCR is useful for rapidly identifying the causative pathogens of meningitis and for examining the clinical course of chemotherapy.


Asunto(s)
Técnicas de Tipificación Bacteriana/métodos , Meningitis Bacterianas/diagnóstico , Reacción en Cadena de la Polimerasa/métodos , Antibacterianos/administración & dosificación , Líquido Cefalorraquídeo/microbiología , Distribución de Chi-Cuadrado , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Gramnegativas/genética , Bacterias Gramnegativas/aislamiento & purificación , Bacterias Grampositivas/efectos de los fármacos , Bacterias Grampositivas/genética , Bacterias Grampositivas/aislamiento & purificación , Haemophilus influenzae/efectos de los fármacos , Haemophilus influenzae/genética , Haemophilus influenzae/aislamiento & purificación , Humanos , Meningitis Bacterianas/microbiología , Sensibilidad y Especificidad , Streptococcus pneumoniae/efectos de los fármacos , Streptococcus pneumoniae/genética , Streptococcus pneumoniae/aislamiento & purificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA